Eli Lilly and Novo Nordisk will continue to compete over the glucagon-like peptide 1 receptor agonist (GLP-1RA) market, with the strong possibility that the two pharmaceutical giants will completely own […]
Novo Nordisk
Trending topics and news from the Novo Nordisk category
Back to news home